$KURA

Kura Oncology (KURA) contributed KO-7246 to Caspian Therapeutics, receiving equity, reimbursement, and service fees. Caspian raised $50M for diabetes and cardiometabolic programs. Kura retains partial ownership and board representation. Kura's core focus remains ziftomenib in AML, with analysts projecting $353.2M revenue and $67.2M earnings by 2029. The Caspian deal adds cardiometabolic upside without significant R&D spending for Kura.

Kura Oncology spun out Caspian, a diabetes-focused company, with $50m in funding led by BVF Partners. Kura retains 50% ownership. Caspian will develop KO-7246, a menin inhibitor for diabetes, using the funds for IND-enabling studies and a second undisclosed inhibitor. Investors include Eli Lilly and T1D Fund.

Kura Oncology's research on a leukemia drug targeting menin showed potential for treating diabetes. The company launched Caspian Therapeutics with $50M in funding to develop menin inhibitors for diabetes and other cardiometabolic diseases. Kura retains 50% ownership, and Caspian will advance its lead drug through early-phase trials.

Kura Oncology (KRRA) launched Caspian Therapeutics with $50M to develop menin inhibitors for diabetes and cardiovascular diseases. Caspian, 50% owned by Kura, aims to start Phase 1 trials for KO-7246 by 2025. Backers include the T1D Fund and Eli Lilly (LLY).

Kura Oncology, Inc. (KURA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (c) Effective as of September 8, 2026, the Board of Directors (the “Board”) of Kura Oncology, Inc. (the “Company”) appointe

Insider trading activity for August 25, 2026, included purchases by executives at TTM Technologies (TTMI), Alpha Metallurgical (AMR), Kura Oncology (KURA), TEAM INC (TISI), and Dorchester Minerals (DMLP). Notable sales occurred at Corpay (CPAY), Aveanna Healthcare (AVAH), Micron Technology (MU), and NLIGHT (LASR). InvestingPro analysis provided fair value assessments for these companies.

Tenax Therapeutics (TENX) rose 27.8% premarket despite a Phase 3 trial setback, planning to discuss revised development plans with the FDA. TherapeuticsMD (TXMD) reported Q2 revenue decline but expects a milestone payment. Kura Oncology (KURA) gained 10.38% on strong Komzifti adoption. Anavex Life Sciences (AVXL) returned to profit in Q3 2026, advancing blarcamesine. Immatics (IMTX) rose 6.78% after a $150M offering. RenovoRx (RNXT) gained 16.40% on positive pancreatic cancer data.

Dick's Sporting Goods (DKS) fell 27% after reporting $5.59B in sales, missing estimates. Dynatrace (DT) rose 3% on a Morgan Stanley upgrade. Shift4 Payments (FOUR) gained 4% after a Wells Fargo upgrade. Moderna (MRNA) climbed 13% following a Wolfe Research upgrade. Marvell (MRVL) jumped 5% on higher price targets. AMD (AMD) rose 5% after a Raymond James upgrade. Kura Oncology (KURA) gained 10% after CEO bought shares. Navitas Semiconductor (NVTS) rose 5% on a $232.8M deal with Claros.

Several biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.

Kura Oncology's stock rose 11.6% in pre-market trading after CEO Troy Wilson bought 100,000 shares for $1.24 million, his second large purchase in a week. Analysts Citigroup and Jefferies reaffirmed positive ratings, citing strong commercial momentum for KOMZIFTI and Q2 earnings beat. The stock surpassed its 52-week high of $12.90.